Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.
Purity:
97.50%
CAS Number:
[947687-12-9]
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted
